Cite
HARVARD Citation
Hamamoto, Y. et al. (2014). A Phase I/II Study of XELIRI Plus Bevacizumab as Second‐Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study). Oncologist. pp. 1131-1132. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hamamoto, Y. et al. (2014). A Phase I/II Study of XELIRI Plus Bevacizumab as Second‐Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study). Oncologist. pp. 1131-1132. [Online].